Sagimet Biosciences Inc. (NASDAQ: SGMT) announced that its AURORA Phase 3 clinical trial of denifanstat, a FASN inhibitor being studied ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE